ASCO: Ivonescimab Improves Progression-Free Survival in EGFR+ Lung Cancer
PFS benefit seen in most subgroups, including those whose disease progressed while receiving third-generation EGFR-TKIs
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.